A Randomized Parallel Comparison of Semaglutide versus Placebo on Intestinal Barrier (SIB)
Investigate the effects of short-term treatment (16 weeks) of semaglutide as compared to placebo on intestinal permeability in subjects with T2D.

Participants should be type 2 diabetic and be treated with metformin only.
Each participant will complete 7-8 visits. After screening, participants will be given either semaglutide or a placebo and will be asked to self-administer the medication once weekly. Study visits will include blood draws and frequent urine samples. Participants will also be asked to provide a stool sample after screening and at their final in-person visit.
Main Procedures Involved: Blood draw, lactulose mannitol ratio test (urine test), vitals, stool samples, subcutaneous injection of semaglutide or placebo once weekly.
Duration of Participation: 5-6 months
18 to 79 years
compensation provided
CU Anschutz non-hospital research facilities
Protocol Number: 21-2774
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers